Catalog No.: PC-63184Not For Human Use, Lab Use Only.
ZGN-1061 (Aclimostat) is a novel potent, selective Methionine aminopeptidase 2 (MetAP2) inhibitor being investigated for treatment of diabetes and obesity.
ZGN-1061 (Aclimostat) is a novel potent, selective Methionine aminopeptidase 2 (MetAP-2) inhibitor being investigated for treatment of diabetes and obesity.
ZGN-1061 reduces body weight in diet-induced obese (DIO) insulin-resistant mice, also produced improvements in metabolic parameters, including plasma glucose and insulin, and, in HepG2 cells, initiated gene changes similar to beloranib.
ZGN-1061 does not increase coagulation markers in dogs and ZGN-1061 has a greatly improved safety profile in rats relative to beloranib.
